Related Experiment Videos
Bone marrow transplantation for severe sickle cell anaemia
A Ferster1, C De Valck, N Azzi
1Hôpital Universitaire des Enfants Reine Fabiola, Free University of Brussels, Belgium.
British Journal of Haematology
|January 1, 1992
Summary
Bone marrow transplantation (BMT) offers a curative and well-tolerated treatment for children with severe sickle cell anaemia. This preliminary study shows promising results, suggesting BMT should be considered for eligible patients.
Area of Science:
- Hematology
- Pediatric Hematology
- Transplantation Medicine
Background:
- Sickle cell anaemia is a severe genetic blood disorder requiring effective treatments.
- Bone marrow transplantation (BMT) is a potential curative option for severe cases.
Purpose of the Study:
- To evaluate the safety and efficacy of busulfan plus cyclophosphamide conditioning regimen for BMT in children with sickle cell anaemia.
- To assess the outcomes and long-term toxicity of BMT in this patient population.
Main Methods:
- Five children with severe sickle cell anaemia received allogeneic BMT.
- Conditioning involved busulfan and cyclophosphamide; GVHD prophylaxis used methotrexate and cyclosporin A.
- Patients were monitored for engraftment, toxicity, and clinical outcomes for 8-28 months.
Main Results:
- BMT was well-tolerated with short durations of neutropenia (14-25 days) and timely platelet recovery (12-45 days).
- No major infections occurred; only one patient experienced mild chronic graft-versus-host disease (GVHD).
- All patients achieved stable haemoglobin levels (>10 g/dl) and demonstrated AS patterns post-transplant, indicating successful engraftment from sickle cell trait donors.
Conclusions:
- BMT is a curative and safe treatment for children with severe sickle cell anaemia.
- The conditioning regimen and GVHD prophylaxis were effective and well-tolerated.
- BMT should be considered as a therapeutic option for suitable patients with sickle cell anaemia.